BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 15771452)

  • 21. Characterization of the binding site of the histamine H3 receptor. 1. Various approaches to the synthesis of 2-(1H-imidazol-4-yl)cyclopropylamine and histaminergic activity of (1R,2R)- and (1S,2S)-2-(1H-imidazol-4-yl)-cyclopropylamine.
    De Esch IJ; Vollinga RC; Goubitz K; Schenk H; Appelberg U; Hacksell U; Lemstra S; Zuiderveld OP; Hoffmann M; Leurs R; Menge WM; Timmerman H
    J Med Chem; 1999 Apr; 42(7):1115-22. PubMed ID: 10197956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
    Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
    J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective histamine H₃ and H₄ receptor agonists exert opposite effects against the gastric lesions induced by HCl in the rat stomach.
    Coruzzi G; Adami M; Pozzoli C; de Esch IJ; Smits R; Leurs R
    Eur J Pharmacol; 2011 Nov; 669(1-3):121-7. PubMed ID: 21839070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold.
    Vaccaro WD; Sher R; Berlin M; Shih NY; Aslanian R; Schwerdt JH; McCormick KD; Piwinski JJ; West RE; Anthes JC; Williams SM; Wu RL; She HS; Rivelli MA; Mutter JC; Corboz MR; Hey JA; Favreau L
    Bioorg Med Chem Lett; 2006 Jan; 16(2):395-9. PubMed ID: 16246552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural variations of 1-(4-(phenoxymethyl)benzyl)piperidines as nonimidazole histamine H3 receptor antagonists.
    Mikó T; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
    Bioorg Med Chem; 2004 May; 12(10):2727-36. PubMed ID: 15110854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Piperidine variations in search for non-imidazole histamine H(3) receptor ligands.
    Łazewska D; Kuder K; Ligneau X; Schwartz JC; Schunack W; Stark H; Kieć-Kononowicz K
    Bioorg Med Chem; 2008 Sep; 16(18):8729-36. PubMed ID: 18774720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diether derivatives of homo- or substituted piperidines as non-imidazole histamine H3 receptor ligands.
    Łazewska D; Kuder K; Ligneau X; Camelin JC; Schunack W; Stark H; Kieć-Kononowicz K
    Bioorg Med Chem; 2009 Apr; 17(8):3037-42. PubMed ID: 19329325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo modulation of rat hypothalamic histamine release by the histamine H3 receptor ligands, immepip and clobenpropit. Effects of intrahypothalamic and peripheral application.
    Jansen FP; Mochizuki T; Yamamoto Y; Timmerman H; Yamatodani A
    Eur J Pharmacol; 1998 Dec; 362(2-3):149-55. PubMed ID: 9874165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of chemical and low-intensity mechanical nociception by activation of histamine H3 receptors.
    Cannon KE; Hough LB
    J Pain; 2005 Mar; 6(3):193-200. PubMed ID: 15772913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the binding distribution of agonist and antagonist ligands for histamine H3 receptors in pig brain by quantitative autoradiography.
    Mezzomo K; Cumming P; Minuzzi L
    Eur J Pharmacol; 2007 Jun; 564(1-3):75-9. PubMed ID: 17350614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists.
    Berlin M; Ting PC; Vaccaro WD; Aslanian R; McCormick KD; Lee JF; Albanese MM; Mutahi MW; Piwinski JJ; Shih NY; Duguma L; Solomon DM; Zhou W; Sher R; Favreau L; Bryant M; Korfmacher WA; Nardo C; West RE; Anthes JC; Williams SM; Wu RL; Susan She H; Rivelli MA; Corboz MR; Hey JA
    Bioorg Med Chem Lett; 2006 Feb; 16(4):989-94. PubMed ID: 16297617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. G protein-dependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations.
    Krueger KM; Witte DG; Ireland-Denny L; Miller TR; Baranowski JL; Buckner S; Milicic I; Esbenshade TA; Hancock AA
    J Pharmacol Exp Ther; 2005 Jul; 314(1):271-81. PubMed ID: 15821027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contractile properties of various histaprodifen derivatives in guinea pig isolated ileum and trachea.
    Christophe B; Carlier B; Schunack W; Chatelain P; Peck M; Massingham R
    Pharmacology; 2007; 79(2):104-13. PubMed ID: 17164592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.
    Elz S; Kramer K; Pertz HH; Detert H; ter Laak AM; Kühne R; Schunack W
    J Med Chem; 2000 Mar; 43(6):1071-84. PubMed ID: 10737740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel partial agonists for the histamine H(3) receptor with high in vitro and in vivo activity.
    Sasse A; Stark H; Reidemeister S; Hüls A; Elz S; Ligneau X; Ganellin CR; Schwartz JC; Schunack W
    J Med Chem; 1999 Oct; 42(20):4269-74. PubMed ID: 10514298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sch 50971, an orally active histamine H3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig.
    McLeod RL; Aslanian R; del Prado M; Duffy R; Egan RW; Kreutner W; McQuade R; Hey JA
    J Pharmacol Exp Ther; 1998 Oct; 287(1):43-50. PubMed ID: 9765320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute central administration of immepip, a histamine H3 receptor agonist, suppresses hypothalamic histamine release and elicits feeding behavior in rats.
    Chiba S; Itateyama E; Sakata T; Yoshimatsu H
    Brain Res Bull; 2009 Apr; 79(1):37-40. PubMed ID: 19150394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acylguanidines as bioisosteres of guanidines: NG-acylated imidazolylpropylguanidines, a new class of histamine H2 receptor agonists.
    Ghorai P; Kraus A; Keller M; Götte C; Igel P; Schneider E; Schnell D; Bernhardt G; Dove S; Zabel M; Elz S; Seifert R; Buschauer A
    J Med Chem; 2008 Nov; 51(22):7193-204. PubMed ID: 18950149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Substituted N-phenylcarbamates as histamine H3 receptor antagonists with improved in vivo potency.
    Reidemeister S; Stark H; Ligneau X; Ganellin CR; Schwartz JC; Schunack W
    Pharmazie; 2000 Feb; 55(2):83-6. PubMed ID: 10723763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and functional characterization of imbutamine analogs as histamine H3 and H4 receptor ligands.
    Geyer R; Kaske M; Baumeister P; Buschauer A
    Arch Pharm (Weinheim); 2014 Feb; 347(2):77-88. PubMed ID: 24493592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.